Investors in Basel-Stadt, Switzerland
Updated 16 Nov 2026
Venture funds
1 funds, by portfolio companies funded in the last 12 months| # | Fund | Sectors | Stages | Leads | Funded, 12 months |
|---|---|---|---|---|---|
| 1 | Novartis Venture Fund Novartis Venture Fund focuses on novel therapeutics and platforms, with recent investments in Hepalink and FoRx Therapeutics. Basel, Switzerland |
Health care, Biotech | Seed, Early stage venture, Late stage venture | 27% | 2 |
Table 1. Investors in Basel-Stadt, Switzerland: venture capital and micro VC funds ranked by companies whose most recent round closed in the last 12 months. Leads is the share of all recorded investments where the fund was lead investor. Source: FundingWatcher. Data as of 16 November 2026.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Investor | Type | Location | Phone | |
|---|---|---|---|---|
| Novartis Venture Fund | Corporate venture arm | Basel, Switzerland | •••@sosei.com | 877 28••• |
| Roche Venture Fund | Corporate venture arm | Basel, Switzerland | •••@roche.com | |
| BioMedPartners | Venture capital firm | Basel, Switzerland | •••@biomedvc.com | +41 61••• |
| Syngenta Ventures | Venture capital firm | Basel, Switzerland | •••@mriseed.com | 800-26••• |
| Kickfund | Venture capital firm | Basel, Switzerland | •••@kickfund.ch | |
| Infinitas Capital | Family office | Basel, Switzerland | •••@infinitas-capital.com | +41 06••• |
| MTIP AG | Private equity firm | Basel, Switzerland | •••@mtip.ch | +41615••• |
| Gebert Rüf Stiftung | Entrepreneurship program | Basel, Switzerland | •••@grstiftung.ch | +41061••• |
8 rows of the CSV in 5 of its 15 columns, email and phone masked.
- 15 of the 38 investors in Basel-Stadt, Switzerland have a published email address, 16 a phone number and 28 a website.
- Novartis Venture Fund has the most recorded investments, 279, 75 of them as lead investor.
- 5 of them are investors in at least one company that closed its most recent round in the last 12 months.
- Novartis Venture Fund is an investor in 2 of those companies, more than any other investor on this list.
- The newest round among their portfolio companies is Cour Pharmaceuticals Development's $50.0M Series B on 18 June 2026.
- Health care is the most common sector across their 71 portfolio companies (61%).
- Seed is the most common investment stage, recorded for 21 of them (55%).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Investors in Basel-Stadt, Switzerland
28 of 38, most investments first| # | Investor | Type | Location | Invests in | Latest portfolio companies | Funded, 12 months | Investments | Lead | Exits | Phone | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Novartis Venture Fund | Corporate venture arm, Venture capital firm | Basel, Switzerland | Health care, Biotech | Hepalink, FoRx Therapeutics | 2 | 279 | 75 | 77 | •••@sosei.com | 877 28••• | |
| 2 | Roche Venture Fund | Corporate venture arm | Basel, Switzerland | Health care, Biotech | Cour Pharmaceuticals Development | 1 | 121 | 15 | 41 | •••@roche.com | In the CSV | |
| 3 | BioMedPartners | Venture capital firm | Basel, Switzerland | Biotech, Health care | TOLREMO therapeutics, Topas Therapeutics, Amal Therapeutics | 87 | 29 | 22 | •••@biomedvc.com | +41 61••• | In the CSV | |
| 4 | Syngenta Ventures | Venture capital firm | Basel, Switzerland | Fintech, Biotech | WeedOut, Tarfin, Agworld | 54 | 9 | 7 | •••@mriseed.com | 800-26••• | ||
| 5 | DayOne accelerator | Startup accelerator, Startup incubator | Basel, Switzerland | 53 | 53 | 1 | In the CSV | |||||
| 6 | Kickfund | Venture capital firm | Basel, Switzerland | Health care, Biotech | a-metal, Adiposs, NXI Therapeutics | 49 | 8 | 1 | •••@kickfund.ch | In the CSV | ||
| 7 | InnoBooster | Startup accelerator | Basel, Switzerland | Artificial intelligence, Health care | Seprify | 1 | 34 | 33 | 0 | +41 61••• | In the CSV | |
| 8 | dRx Capital | Corporate venture arm, Venture capital firm | Basel, Switzerland | Biotech, Health care | Dopavision | 31 | 4 | 8 | In the CSV | |||
| 9 | Helvetia Venture Fund | Venture capital firm | Basel, Switzerland | Fintech, Health care | FAAREN Group GmbH, INKI.TECH, Urban Connect | 30 | 16 | 3 | +41058••• | In the CSV | ||
| 10 | Infinitas Capital | Family office, Venture capital firm | Basel, Switzerland | Education, Hardware | einwert, Storypod, Olsam Group | 26 | 4 | 4 | •••@infinitas-capital.com | +41 06••• | In the CSV | |
| 11 | MTIP AG | Private equity firm | Basel, Switzerland | Health care, Artificial intelligence | NitiNotes, Hexarad, Apricity | 22 | 13 | 4 | •••@mtip.ch | +41615••• | In the CSV | |
| 12 | Gebert Rüf Stiftung | Entrepreneurship program, Government investment office | Basel, Switzerland | Biotech, Health care | NXI Therapeutics, Hemotune, POLYNEURON | 22 | 11 | 0 | •••@grstiftung.ch | +41061••• | In the CSV | |
| 13 | kineo finance | Venture debt fund | Basel, Switzerland | 15 | 7 | 0 | In the CSV | |||||
| 14 | LifeCare Partners | Private equity firm | Basel, Switzerland | Biotech | Kupando | 1 | 10 | 7 | 2 | +41 (0••• | ||
| 15 | AVANTECA Partners | Private equity firm | Basel, Switzerland | 7 | 2 | 0 | In the CSV | |||||
| 16 | EVA Basel | Entrepreneurship program, Venture capital firm | Basel, Switzerland | Health care, Biotech | Inthera Bioscience, AOT - Advanced Osteotomy Tools | 6 | 3 | 2 | •••@eva-basel.ch | +41612••• | In the CSV | |
| 17 | Sallfort Privatbank AG | Investment bank, Venture capital firm | Basel, Switzerland | 6 | 2 | 2 | •••@sallfort.com | +41 44••• | In the CSV | |||
| 18 | Bulb Capital | Venture capital firm | Basel, Switzerland | 3 | 2 | 0 | •••@bulbcapital.com | In the CSV | ||||
| 19 | New Energies Invest | Venture capital firm | Basel, Switzerland | 3 | 1 | 2 | •••@newenergies.ch | +41 61••• | ||||
| 20 | Varuma | Micro VC fund, Venture capital firm | Basel, Switzerland | 3 | 0 | 2 | •••@varuma.ch | |||||
| 21 | CPV / CAP Pension Fund Coop. | Pension fund | Basel, Switzerland | 2 | 1 | 0 | +41 61••• | In the CSV | ||||
| 22 | Swiss Health Angels | Angel group | Basel, Switzerland | 2 | 0 | 0 | In the CSV | |||||
| 23 | Clearance Ventures | Venture capital firm | Basel, Switzerland | 1 | 0 | 0 | •••@clearanceventures.com | +41 61••• | In the CSV | |||
| 24 | Erfindungs Verwertung | Venture capital firm | Basel, Switzerland | 1 | 0 | 0 | +41 61••• | In the CSV | ||||
| 25 | Neuromuscular Research Association Basel | Government investment office | Basel, Switzerland | 1 | 0 | 0 | ||||||
| 26 | Around Capital | Family office, Startup incubator | Basel, Switzerland | 0 | 0 | 0 | •••@aroundcapital.com | In the CSV | ||||
| 27 | Michael Bornhaeusser | Basel, Switzerland | 0 | 0 | 0 | In the CSV | ||||||
| 28 | The i4Challenge | Startup accelerator | Basel, Switzerland | 0 | 0 | 0 |
Table 2. Investors in Basel-Stadt, Switzerland: the first 28 by recorded investments with a website and a location. Email and phone are masked here and complete in the CSV. Source: FundingWatcher. Data as of 16 November 2026. Base: 38.
Most active in the last 12 months
By portfolio companies funded| # | Investor | Location | Funded, 12 months | Portfolio | Latest |
|---|---|---|---|---|---|
| 1 | Novartis Venture Fund | Basel, Switzerland | 2 | 20 | Hepalink, FoRx Therapeutics |
| 2 | Roche Venture Fund | Basel, Switzerland | 1 | 3 | Cour Pharmaceuticals Development |
| 3 | LifeCare Partners | Basel, Switzerland | 1 | 1 | Kupando |
| 4 | InnoBooster | Basel, Switzerland | 1 | 7 | Seprify |
| 5 | Wecken & Cie. | Basel, Switzerland | 1 | 6 | happyhotel |
Table 3. Investors in Basel-Stadt, Switzerland: investors in the most companies whose most recent round falls in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Latest rounds in their portfolios
Newest first| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors on this list | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Cour Pharmaceuticals Development | Cour Pharmaceuticals Development develops nanoparticle technology to reset immune systems in multiple sclerosis patients. | Biotech | Skokie, United States | Series B | $50.0M | 2026-06-18 | $185.5M | Roche Venture Fund | 51 to 100 | 2015 |
| Kupando | Kupando is a biopharmaceutical company developing agonists that stimulate innate immunity. | Biotech | Schönefeld, Germany | Series A | $11.5M | 2026-03-18 | $24.0M | LifeCare Partners | 1 to 10 | 2018 |
| happyhotel | happyhotel offers an AI sales manager that automates the sales process for hotels. | Artificial intelligence | Offenburg, Germany | Series A | $7.7M | 2026-02-19 | $7.7M | Wecken & Cie. | 11 to 50 | 2019 |
| FoRx Therapeutics | FoRx Therapeutics is a biotechnology company developing cancer drugs that target DNA replication stress pathways. | Biotech | Basel, Switzerland | Series A | $50.0M | 2025-12-18 | $109.4M | Novartis Venture Fund | 11 to 50 | 2019 |
Table 4. Investors in Basel-Stadt, Switzerland: the 4 most recent rounds of companies they back. Source: FundingWatcher. Data as of 16 November 2026.
Portfolio sectors
| Portfolio sectors | Companies | Share |
|---|---|---|
| Health care | 43 | 61% |
| Biotech | 35 | 49% |
| Software | 22 | 31% |
| Artificial intelligence | 8 | 11% |
| Hardware | 5 | 7% |
| Fintech | 3 | 4% |
| Commerce | 2 | 3% |
| Education | 1 | 1% |
Table 5. Investors in Basel-Stadt, Switzerland: portfolio companies by sector. Source: FundingWatcher. Data as of 16 November 2026.
Investment stages
| Investment stages | Investors | Share |
|---|---|---|
| Seed investors | 21 | 55% |
| Early stage investors | 20 | 53% |
| Late stage investors | 13 | 34% |
| Venture investors | 9 | 24% |
| Post IPO investors | 4 | 11% |
| Grant makers | 4 | 11% |
| Private equity investors | 3 | 8% |
| Convertible note investors | 2 | 5% |
Table 6. Investors in Basel-Stadt, Switzerland by stage they invest at. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Investors | Share |
|---|---|---|
| Basel | 37 | 97% |
| Riehen | 1 | 3% |
Table 7. Investors in Basel-Stadt, Switzerland by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Founded
| Founded | Investors | Share |
|---|---|---|
| 2020s | 3 | 12% |
| 2010s | 7 | 29% |
| 2000s | 6 | 25% |
| 1990s | 6 | 25% |
| 1900s | 1 | 4% |
| 1850s | 1 | 4% |
Table 8. Investors in Basel-Stadt, Switzerland by founding decade. Source: FundingWatcher. Data as of 16 November 2026.
Method
- An investor is on this list when its headquarters is in Basel-Stadt, Switzerland. On 16 November 2026 that is 38 investors.
- 15 rows carry an email address and 16 a phone number from the investor file. Investments, lead investments and exits are the counts the source records.
- The table prints the first 28 rows by recorded investments that carry a website and a location, with email and phone masked. The CSV carries all 38 rows: 10 have no website and 0 no location.
Sources, fields and exclusions of both files: Method.
Questions
- How many investors in Basel-Stadt, Switzerland are on the list?
- 38, in the file dated 16 November 2026. 5 of them invested in a company whose most recent round falls in the last 12 months.
- How many have an email address?
- 15 of the 38 carry an email address in the download and 16 a phone number.
- What does the CSV contain?
- One row per investor, 15 columns: name, types, stages, city, region, country, founded, website, linkedin, investments, funded_last_12m, exits, lead_investments, email, phone.
- How much does the list cost?
- $29 one-time for all 38 rows, no account. Every investor and every startup, two files, cost $99. With partner contacts, up to 2 per firm compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV with 38 rows, 15 firm email addresses and 16 phone numbers, on the page after payment and by mail. The emails are the address a firm publishes: 10 of the 15 are inboxes such as info@ or contact@. No partner names.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.